OTCMKTS:OPHLF Ono Pharmaceutical 5/7/2025 Earnings Results & Report $14.95 0.00 (0.00%) As of 10/9/2026 Ono Pharmaceutical was expected to report earnings on May 7, 2025. Analysts expected earnings of $0.0922 per share on revenue of $805.38 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileEarnings HistoryForecast Earnings Announcement Details Announcement DateMay 7, 2025 Ono Pharmaceutical EPS ResultsActual EPSN/AConsensus EPS $0.0922Beat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersOno Pharmaceutical Revenue ResultsActual RevenueN/AExpected Revenue$805.38 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Ono Pharmaceutical Earnings FAQ When is Ono Pharmaceutical's next earnings date? Ono Pharmaceutical's next earnings date is estimated for Wednesday, October 28, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ono Pharmaceutical on the company's earnings history page. Ono Pharmaceutical Earnings HeadlinesBiohaven licenses IgG degrader portfolio to Japan’s OnoOctober 8 at 6:20 PM | seekingalpha.comOno’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F InvestorsOctober 6, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 10 at 1:00 AM | Porter & Company (Ad)Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?September 24, 2026 | finance.yahoo.comOno Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesSeptember 1, 2026 | businesswire.comOno Pharma’s New Cancer Trial Adds Early-Stage Upside—and Risk—for OPHLF InvestorsAugust 26, 2026 | tipranks.comSee More Ono Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ono Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ono Pharmaceutical and other key companies, straight to your email. Email Address About Ono PharmaceuticalOno Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of prescription medicines. The company focuses primarily on oncology, immunology, neurology and other specialty therapeutic areas, with an emphasis on discovering treatments for diseases with significant unmet medical needs. Ono’s best-known product is Opdivo (nivolumab), an immuno-oncology medicine developed in collaboration with Bristol Myers Squibb and approved for multiple cancer indications in various markets. The company also markets and develops additional medicines through its own research programs and collaborations with global pharmaceutical and biotechnology companies. Founded in Osaka in 1717 as a pharmaceutical wholesaler, Ono has evolved into a research-based drug manufacturer with operations and commercial activities in Japan and international markets. Its products are distributed globally through subsidiaries and strategic partnerships. The company is headquartered in Osaka, Japan, and is led by President and Chief Executive Officer Gyo Sagara.View Ono Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
